BN Business News
Add your company to Business Communicator →

Finance & markets · 18/11/20261 min read

Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach

EDITORIAL ILLUSTRATIONF&Finance & marketsBN
Illustration generated by Business News; it is not a source photograph.

Summary

EC approval follows recent U.S. FDA approval of Biocon's pertuzumab biosimilar Provides an additional treatment option for patients with HER2-positive breast cancer and may support more sustainable healthcare systems in Europe The milestone further strengthens Biocon's growing oncology...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →